10:15 AM EST - Resverlogix Corp. : Announced today that all patients active in BETonMACE, the Company’s event-based, phase 3 registration trial, recently completed their final, follow-up safety visits, marking another important step towards trial completion. Given the remaining steps required to finalize BETonMACE, the Company anticipates being in a position to provide top-line results in September. Resverlogix Corp.
shares T.RVX are trading up $0.04 at $3.02.
